Who are Tzield's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Talvey, Epkinly, Orthoclone Okt3, EPKINLY, TALVEY, TECVAYLI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teplizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Tzield — Competitive Intelligence Brief

Tzield (TEPLIZUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD3-directed Antibody [EPC]. Area: Metabolic.

marketed CD3-directed Antibody [EPC] T-cell surface glycoprotein CD3 Metabolic Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Tzield (TEPLIZUMAB) — Provention Bio Inc. Tzield works by binding to the CD3 complex on T-cells, preventing them from attacking pancreatic beta cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tzield TARGET	TEPLIZUMAB	Provention Bio Inc	marketed	CD3-directed Antibody [EPC]	T-cell surface glycoprotein CD3	2022-01-01
Talvey	TALQUETAMAB	Janssen Biotech	marketed		T-cell surface glycoprotein CD3	2023-01-01
Epkinly	EPCORITAMAB	Genmab Us, Inc.	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	T-cell surface glycoprotein CD3	2023-01-01
Orthoclone Okt3	MUROMONAB-CD3	Ortho Biotech	marketed	CD3 Blocker Immunosuppressant	T-cell surface glycoprotein CD3	1992-01-01
EPKINLY	EPCORITAMAB-BYSP	GENMAB US, INC.	marketed		B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3
TALVEY	TALQUETAMAB-TGVS	JANSSEN BIOTECH	marketed		G-protein coupled receptor family C group 5 member D, T-cell surface glycoprotein CD3
TECVAYLI	TECLISTAMAB-CQYV	JANSSEN BIOTECH	marketed		Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD3-directed Antibody [EPC] class)

PROVENTION BIO INC · 1 drug in this class
Provention Bio Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tzield — Competitive Intelligence Brief. https://druglandscape.com/ci/teplizumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab